Title

Feature | Thrombosis and COVID-19: FAQs For Current Practice

Authors

Geoffrey D. Barnes
Adam Cuker
Tyler J Gluckman, Providence Heart and Vascular Institute, Portland, OR, USA.Follow
Gregory Piazza
Deborah M. Siegal

Document Type

News Article

Publication Date

4-22-2020

Publication Title

American College of Cardiology: Cardiology Magazine

Keywords

2019-nCoV; cards; cards publication; Anticoagulants, Heparin, Low-Molecular-Weight, Heparin, Venous Thromboembolism, Critical Illness, Fibrinolytic Agents, Fibrinogen, Patient Discharge, Superinfection, Respiration, Artificial, Netherlands, COVID-19, Coronavirus, Coronavirus Infections, International Normalized Ratio

Abstract

An FAQ on the potential impact of COVID-19 on thrombotic and/or bleeding risk from ACC's Science and Quality Committee summarize the current data on the risk, potential need for hemostasis/coagulation testing, VTE prophylaxis, and therapeutic anticoagulation in patients with COVID-19 without confirmed/suspected thrombosis.

Clinical Institute

Cardiovascular (Heart)

Department

Cardiology

Department

Infectious Diseases

Department

Center for Cardiovascular Analytics, Research + Data Science (CARDS)

Recommended Citation

Barnes, Geoffrey D.; Cuker, Adam; Gluckman, Tyler J; Piazza, Gregory; and Siegal, Deborah M., "Feature | Thrombosis and COVID-19: FAQs For Current Practice" (2020). Articles, Abstracts, and Reports. 3952.
https://digitalcommons.providence.org/publications/3952